KBY Biotech Indexv0.0.34
Search
← Pipeline|Kemanaritide

Kemanaritide

Phase 3
FAT-1071
By Fate Ther
Source: Trial-derived·Trials: 4
Modality
ADC
MOA
USP1i
Target
JAK2
Pathway
Fibrosis
ACC
Development Pipeline
Preclinical
~Apr 2013
→ ~Jul 2014
Phase 1
~Oct 2014
→ ~Jan 2016
Phase 2
~Apr 2016
→ ~Jul 2017
Phase 3
Oct 2017
→ Nov 2030
Phase 3Current
NCT07644084
89 pts·ACC
2023-08→2028-10·Completed
NCT07357278
1,161 pts·ACC
2017-10→2030-11·Active
NCT04702307
1,034 pts·ACC
2019-06→2028-09·Completed
+1 more trial
3,122 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2027-06-051.2y awayPh3 Readout· ACC
2028-09-242.5y awayPh3 Readout· ACC
2028-10-062.5y awayPh3 Readout· ACC
2030-11-134.6y awayPh3 Readout· ACC
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P3
Active
P3
Complet…
P3
Complet…
P3
Complet…
Catalysts
Ph3 Readout
2027-06-05 · 1.2y away
ACC
Ph3 Readout
2028-09-24 · 2.5y away
ACC
Ph3 Readout
2028-10-06 · 2.5y away
ACC
Ph3 Readout
2030-11-13 · 4.6y away
ACC
ActiveCompleted|StartCompletionToday
Trials (4)
NCTPhaseIndicationStatusNEP
NCT07644084Phase 3ACCCompleted89EDSS
NCT07357278Phase 3ACCActive1161SRI-4
NCT04702307Phase 3ACCCompleted1034EFS
NCT07275450Phase 3ACCCompleted838Mayo
Competitors (10)
DrugCompanyPhaseTargetMOA
SNY-2934SanofiPhase 3KRASG12DUSP1i
AMG-9052AmgenPhase 2/3CDK2USP1i
DatozumabRegeneronPhase 1B7-H3USP1i
GMA-729GenmabPhase 2BCL-2USP1i
GMA-5010GenmabPhase 3JAK2TROP-2 ADC
PexanaritideInnovent BioPreclinicalSGLT2USP1i
TeravorutinibIlluminaPhase 2JAK2PRMT5i
ROI-9675Roivant SciencesNDA/BLAHER2USP1i
AXS-4984AxsomePreclinicalJAK2BiTE
CapirapivirTG TherapeuticsApprovedJAK2AuroraAi